BACKGROUND: Xuezhikang (XZK) is an extract of fermented red @entity375 @entity579 that has lipid-lowering properties. OBJECTIVE: To evaluate the effects of XZK on lipids in subjects with @entity2299 but no @entity301 . METHODS: A total of 116 adults with baseline non-high-density lipoprotein @entity165 (non-HDL-C) levels of approximately 208  mg/dL and low-density lipoprotein @entity165 (LDL-C) levels of approximately 175  mg/dL were randomized to either placebo or XZK 1200 or 2400  mg daily and treated for 12  weeks. RESULTS: A majority of the @entity1 were white (53.4%) or Asian (37.1%). Daily XZK 1200  mg and 2400  mg for 4 to 12  weeks resulted in statistically significant (P  <  .001) and clinically meaningful decreases in non-HDL-C (   24% reduction) and LDL-C (   27% reduction) compared with placebo. XZK treatment at either dose enabled approximately 50% of subjects to reduce their LDL-C levels by  >=   30%. Doubling the XZK daily dose from 1200 to 2400  mg at treatment week 8 caused an additional 4.6% reduction in LDL-C. Significant benefits were also observed across secondary efficacy variables, including total @entity165 (TC), @entity755 ( @entity755 ), @entity1674 , HDL-C, the TC/HDL-C ratio, and the @entity755 / @entity1675 ratio, at treatment week 8 or 12. XZK was safe and well tolerated. Safety and tolerability profiles were similar across treatment groups. Most adverse events were gastrointestinal. No subject experienced @entity121 or markedly elevated liver transaminases or @entity908 kinase. CONCLUSION: Xuezhikang significantly reduced non-HDL-C and LDL-C, and was well tolerated. Further, longer-term studies in more diverse @entity1 populations are needed to corroborate these findings.

Effects of Xuezhikang in XXXX with @entity2299 : A multicenter, randomized, placebo-controlled study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity755 :: ('338', 'Gene') :: ['Apo B', 'apolipoprotein B'] @entity1675 :: ('335', 'Gene') :: ['Apo A-I'] @entity375 :: ('4932', 'Species') :: ['yeast'] @entity579 :: ('4530', 'Species') :: ['rice'] @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathy'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1 :: (9606,Species) :: ['patients']
